Cardiac Rhythm Management Market Worth 27.8 Billion Dollars by 2021, Says visiongain Report

LONDON, December 10, 2011 -



www.visiongain.com/Report/728/Cardiac-Rhythm-Management-Devices-World-Market-Outlook-2011-2021

A new report by visiongain, a London-based business information provider, predicts the global cardiac rhythm management market to be worth $27.8bn by 2021. The market generated $14.6bn in 2010 according to Cardiac Rhythm Management Devices: World Market Outlook, 2011-2021, published in December 2011.

Cardiac rhythm management is a well established segment of the cardiology devices market. Cardiac rhythm management devices are commonly used for the treatment of arrhythmias and heart failure. The cardiac rhythm management market has an opportunity to expand with the increasing prevalence of arrhythmias, especially in emerging economies.

James Sheppard, healthcare industry analyst, says ‘The cardiac rhythm management market has enjoyed strong growth over recent years, despite the economic downturn. Although the market has started to witness slump in the developed markets of the US and EU, there are opportunities for the device makers to expand in the developing economies. Growth will also be driven by new technology such as wireless pacemakers, novel cardiac resynchronisation devices and cardiac ablation devices. Over the course of the next decade there will be greater demand for cardiac rhythm management devices as the number of people suffering from arrhythmias increase.’

Visiongain’s research suggests that the cardiac rhythm management market will benefit from the growth of emerging economies. Increasing wealth in China and India will lead to an increase in lifestyle-related disorders and heart problems that may result in the need of a cardiac rhythm management device. Mature markets such as the US and Japan will experience slower growth as the markets reach maturity and achieve high penetration rates.

Cardiac rhythm management is a well established market with significant opportunities to grow. Visiongain’s analysis of the implantable cardioverter defibrillator (ICD), pacemaker, cardiac resynchronisation therapy (CRT) and cardiac ablation pipelines showed a great deal of promise in the future. A number of new innovative products will dominate the market during the forecast period. Visiongain’s analysis of the three main competitors in the cardiac rhythm management market suggests that innovation will drive the market.

To view sample pages please click on:

www.visiongain.com/Report/728/Cardiac-Rhythm-Management-Devices-World-Market-Outlook-2011-2021

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

1. Executive Summary

1.1 Cardiac Rhythm Management Devices Market Highlights

1.2 Overview of Chapter Content

1.3 Research and Analysis Methods

1.4 Glossary of Terms Relating to Cardiac Rhythm Management Devices

2. Introduction

2.1 Cardiac Rhythm Management Definition

2.2 The Heart

2.3 Cardiac Rhythm Disorders

2.3.1 Heart Failure

2.3.2 Arrhythmias

2.3.2.1 Tachycardia

2.3.2.2 Bradycardia

2.4 Cardiac Rhythm Management Devices

2.4.1 Pacemakers

2.4.1.1 History of Pacemakers

2.4.2 Implantable Cardioverter Defibrillators (ICD)

2.4.2.1 History of ICD Devices

2.4.3 Cardiac Resynchronisation Therapy (CRT)

2.4.4 Cardiac Ablation Devices

2.5 Regulation of Cardiac Rhythm Management Devices

2.5.1 The US Regulation System

2.5.2 The European Regulation System

2.5.2.1 Post Marketing Surveillance in the EU

3. The Global Cardiac Rhythm Management Devices Market, 2010-2021

3.1 Cardiac Rhythm Management Devices: Market Overview

3.1.1 The Cardiac Rhythm Management Devices Market in 2010

3.2 Regional Market Breakdown, 2010

3.2.1 The US and Japanese Markets

3.2.2 The European Market

3.2.3 The Chinese and Indian Markets

3.3 Global Cardiac Rhythm Management Devices Market Forecast, 2011-2015

3.4 Global Cardiac Rhythm Management Devices Market Forecast, 2015-2021

3.5 Leading Regional Markets for Cardiac Rhythm Management Devices, 2011-2021

3.5.1 The US, European and Japanese Markets, 2011-2021

3.5.1.1 The US Market

3.5.1.2 The European Markets

3.5.1.3 The Japanese Market

3.5.2 The Chinese and Indian Markets, 2011-2021

3.5.2.1 The Chinese Market

3.5.2.2 The Indian Market

4. The Implantable Cardioverter Defibrillator (ICD) Market, 2010-2021

4.1 Chapter Overview

4.2 Leading Companies in the Defibrillator Market, 2010

4.3 The ICD Market in 2010

4.3.1 Regional Breakdown of the ICD Market

4.3.2 Leading Products in the ICD Market, 2010

4.4 The ICD Market Forecast, 2011-2021

4.4.1 The ICD Market Forecast, 2011-2015

4.4.2 The ICD Market Forecast, 2015-2021

4.5 The ICD Market Pipeline

4.5.1 AnalyST Accel ICD (St. Jude Medical)

4.5.2 Paradym RF (Sorin Group)

4.5.3 PICD- Percutaneous Implantable Cardioverter Defibrillator (InnerPulse)

4.5.4 S-ICD System (Cameron Health)

4.5.5 Other Devices

4.5.6 Remote Monitoring

4.6 SWOT Analysis of the ICD Market, 2011-2021

4.6.1 Strengths

4.6.1.1 ICD Devices are More Effective than Anti-Arrhythmia Drugs

4.6.1.2 Continuous Innovation in the Industry

4.6.2 Weaknesses

4.6.2.1 Safety Concerns Regarding ICD Devices

4.6.2.2 Longevity of Devices

4.6.3 Opportunities

4.6.3.1 Aging Population will Lead to an Increased Patient Base

4.6.3.2 Increasing Use of ICD Devices as Prophylactics

4.6.3.3 Emerging Markets Offer Growth Opportunities

4.6.4 Threats

4.6.4.1 Only a Small Number of Companies Operate in The Largest CRM Devices Market

4.6.4.2 Anti Arrhythmia Drugs May Become More Effective

5. The Pacemaker Market, 2010-2021

5.1 Chapter Overview

5.2 Medtronic Dominates the Pacing Devices Market

5.3 The Pacemaker Market in 2010

5.3.1 Dual-Chamber Pacemakers Dominate the Market in 2010

5.3.2 Regional Breakdown of the Pacemaker Market

5.3.3 Leading Products in the Pacemaker Market

5.4 The Pacemaker Market Forecast, 2011-2021

5.5 The Pacemaker Market Segments, 2010-2021

5.5.1    The Dual-Chamber Pacemaker Market, 2010

5.5.1.1 The Dual-Chamber Pacemaker Market, 2011-2015

5.5.1.2 The Dual-Chamber Pacemaker Market, 2015-2021

5.5.2 The Single Chamber Pacemaker Market, 2010

5.5.2.1 The Single Chamber Pacemaker Market, 2011-2021

5.5.3 The External Pacemaker Market, 2010

5.5.3.1 The External Pacemaker Market, 2011-2021

5.6 The Pacemaker Pipeline

5.6.1 Evia ProMRI Pacemaker Series (BioTronik)

5.6.2 Revo MRI SureScan (Medtronic)

5.6.3 Leadless Pacemakers (Medtronic)

5.6.4 Accent MRI Pacemaker (St. Jude Medical)

5.6.5 SOPHOS 455 (Medico)

5.6.6 Biological Pacemakers (UC Davis)

5.6.7 Stem Cells for the Treatment of Arrhythmias

5.7 SWOT Analysis of the Pacemaker Market, 2011-2021

5.7.1 Strengths

5.7.1.1 Pacemakers are Proven to Save Lives

5.7.1.2 Mature Segment of the Market

5.7.2 Weaknesses

5.7.2.1 Safety Concerns Regarding Pacemakers

5.7.2.2 Longevity of Pacemakers

5.7.3 Opportunities

5.7.3.1 Aging Population Will Increase the Number of Patients Requiring Pacemakers

5.7.3.2 Emerging Economies Will Drive Growth

5.7.4 Threats

5.7.4.1 Only a Small Number of Companies Operate in the Market

5.7.4.2 Biologics and Stem Cells May Become More Important than Artificial Pacemakers

6. The Cardiac Resynchronisation Therapy Devices (CRT) Market, 2010-2021

6.1 Chapter Overview

6.2 The Cardiac Resynchronisation Therapy Market in 2010

6.2.1    Leading Segments in the CRT Market

6.2.2 Leading Products and Companies in the CRT Market

6.3 Cardiac Resynchronisation Therapy Market Forecast, 2011-2021

6.3.1 Cardiac Resynchronisation Therapy Market Forecast, 2011-2015

6.3.2 The Cardiac Resynchronisation Therapy Market Forecast, 2015-2021

6.4 Cardiac Resynchronisation Therapy Pipeline, 2011

6.4.1 Consulta CRT-P (Medtronic)

6.4.2 Optimizer III (Impulse Dynamics)

6.4.3 Unify QUADRA (St. Jude Medical)

6.4.4 SonR System (Sorin Group)

6.5 SWOT Analysis of the Cardiac Resynchronisation Therapy Market, 2011-2021

6.5.1 Strengths

6.5.1.1 CRT has a Broad Range of Indications

6.5.1.2 Combination Products Offer Wider Potential Market

6.5.2 Weaknesses

6.5.2.1 Safety Concerns Surrounding CRT

6.5.2.2 Longevity of Devices

6.5.2.3 Low Awareness of Technology in Emerging Economies

6.5.3 Opportunities

6.5.3.1 Aging Population Will Increase the Target Population for CRT Devices

6.5.3.2 Positive Trial Data Will Help to Stimulate Growth

6.5.4 Threats

6.5.4.1 Drugs May Become More Important Than CRT Devices

7. The Cardiac Ablation Devices Market, 2010-2021

7.1 Chapter Overview

7.2 The Cardiac Ablation Devices Market in 2010

7.2.1 The US was the Largest Market for Cardiac Ablation in 2010

7.2.2 Leading Products in the Cardiac Ablation Market

7.3 Cardiac Ablation Market Forecast, 2011-2021

7.3.1 Cardiac Ablation Market Forecast 2011-2015

7.3.2 The Cardiac Ablation Market Forecast, 2015-2021

7.4 The Cardiac Ablation Pipeline

7.4.1 HeartLight Endoscopic Ablation System (CardioFocus)

7.4.2 The Bard HD Mesh Ablator Catheter (C.R. Bard Electrophysiology)

7.4.3 High Intensity Focused Ultrasound (HIFU) Ablation (ProRhythm)

7.4.4 ATRILAZE Surgical Ablation System (MedicalCV)

7.4.5 Cardiac Ablation Visualisation System (Endosense & Siemens Healthcare)

7.5 SWOT Analysis of the Cardiac Ablation Market

7.5.1 Strengths

7.5.1.1 Current Ablation Therapies are More Effective Than Predecessors

7.5.1.2 Continuous Innovation in the Industry

7.5.1.3 Products Available Now Are Unlikely to Be Market Leaders in Ten Years

7.5.2 Weaknesses

7.5.2.1 Increasing Consolidation in the Market Creating Entry Barriers

7.5.2.2 High Barriers to Entry Threaten to Stifle Innovation

7.5.3 Opportunities

7.5.3.1 Increasing Prevalence of Atrial Fibrillation

7.5.3.2 Emerging Markets Offer Significant Opportunity for Growth

7.5.4 Threats

7.5.4.1 Drugs May Become More Important Than the Ablation Procedure

8. Leading Companies in the Cardiac Rhythm Management Market, 2010

8.1 Boston Scientific

8.1.1 Boston Scientific Sales, 2010

8.1.2 Boston Scientific’s Cardiac Rhythm Management Sales, 2010

8.1.3 Boston Scientific Cardiac Rhythm Management Devices Rankings, 2010

8.1.4 Boston Scientific Pipeline

8.2 Medtronic

8.2.1    Medtronic Sales, 2010

8.2.2 Medtronic Cardiac Rhythm Management Sales, 2010

8.2.3 Medtronic Cardiac Rhythm Management Rankings, 2010

8.2.4 Medtronic Pipeline, 2010

8.3 St. Jude Medical

8.3.1 St. Jude Medical Sales, 2010

8.3.2 St. Jude Medical Cardiac Rhythm Management Sales, 2010

8.3.2.1 St. Jude Medical Cardiac Ablation Sales, 2010

8.3.3 St. Jude Medical Cardiac Rhythm Management Rankings, 2010

8.3.4 St. Jude Medical Pipeline

8.4 Other Companies in the Cardiac Rhythm Management Market

9. Expert Opinions

9.1 Dr. Gideon Meiry, Former CTO, Odem Medical

9.1.1 The CRT Market

9.1.2 The Future of the CRT Market

9.1.3 Remote Monitoring

9.2 Dr. Mauro Biffi, Senior Electrophysiologist, University of Bologna

9.2.1 The CRM Market

9.2.2 The Future of the CRM Market

9.2.3 Remote Monitoring

10.    Conclusions

10.1 The Cardiac Rhythm Management Devices Market, 2010-2021

10.1.1 Growth Will be Driven by Emerging Markets

10.2 The Implantable Cardioverter Defibrillator Market, 2010-2021

10.3 The Pacemaker Market, 2010-2021

10.4 The Cardiac Resynchronisation Therapy Market, 2010-2021

10.5 The Cardiac Ablation Devices Market, 2010-2021

Appendix A

Appendix B

Visiongain report evaluation form

Companies Listed

3M pharmaceuticals

Abbott Laboratories

Ablation Frontiers

ARCO

Astra Zeneca

AtriCure

ATS Medical

Aventis

Biosense Webster

BioTronik

Boston Scientific

Bristol-Myers Squibb

C.R Bard

C.R Bard Electrophysiology

Cameron Health

CardioFocus

Center for Devices and Radiological Health (CDRH)

CryoCath Technologies

CryoCor

Endosense

European Heart Rhythm Association (EHRA)

FDA’s MedWatch

Food and Drug Administration (FDA)

Global Harmonization Task Force

Guidant Corporation

Hansen Medical

Impulse Dynamics

InnerPulse

Japanese Ministry of Health, Labour and Welfare (MHLW)

John Hopkins University Medical School

Johnson & Johnson

Karolinska Institute

MedicalCV

Medico

MediVed

Medtronic

MHRA (Medicines and Healthcare Products Regulatory Agency)

New York Heart Association

Odem Medical

Pfizer

ProRhythm

Rainbow Medical

Shree Pacetronix

Siemens Healthcare

Sinai Hospital, Baltimore

Sorin Group

St. Jude Medical

Stony Brook University

Transurgical

UC Davis

University of Bologna

University of Missouri

US Bankruptcy Court for the District of Delaware

World Society of Arrhythmias

Wyeth

Zoll Medical Corporation

Please contact Sara Peerun for an exec summary or a more detailed overview of this report:

Email: sara.peerun@visiongainglobal.com

Tel: +44(0)20-7336-6100

.